COVID-19 Vaccines Clinical Trial
Official title:
Comparative Evaluation of Covid-19 Vaccines Response and Progression in Different Covid-19 Vaccines Groups
Study Population Population with vaccinated with three different Covid Vaccines (Inactive Vaccine (Sinovac Life Sciences, Beijing, China), recombinant human adenovirus serotype number 26 (rAd26 of Sputnik V), mRNA Vaccine (Pfizer/BionTEC). This is multi center study, 5 centers will be joined to study from different part of the country. Approximately 1500 people will be enrolled to study.
Aim of Study - to evaluate Anti-SARS-CoV-2 IgG Antibody and Neutralizing Antibody response in different Vaccine Groups - to evaluate progression of the vaccine response after 2, 6, and 12 Months after Vaccination in different Vaccine Groups, and compare antibody response in different Vaccines Group. - It was also aimed to evaluate effect of the age, gender, co-morbid conditions such as COPD, DM, Heart Failure, Covid Infection on IgG Antibody and Neutralizing Antibody response. Anti SARS CoV2 IgG antibody levels will be measured with chemiluminescence method (CHEM) by using ADVIA Centaur XP Immunassay System (Siemens Helthcare, GmbH, Germany) and Anti SARS CoV2 IgG reactive (Siemens Helthineers, GmbH, Germany). Neutralizing Capacity of Anti-SARS-CoV-2 Antibodies against SARS CoV2 levels will be determined with ELISA method (ELx 808, ELISA Microplate Absorbance Reader, BioTek Instruments Inc, Winooski, VT, USA) by using Euroimmun SARS-CoV-2 NeutraLISA Assay (EUROIMMUN, Medizinische Labordiagnostika AG, Germany). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05918939 -
UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study)
|
Early Phase 1 | |
| Active, not recruiting |
NCT06272253 -
UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects
|
Early Phase 1 | |
| Recruiting |
NCT05298800 -
Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23
|
Phase 4 | |
| Recruiting |
NCT05185817 -
Effectiveness of COVID-19 Vaccine in Hematopoietic Stem Cell Transplant Patients
|
Phase 2 | |
| Not yet recruiting |
NCT04876885 -
The Future of Viral Communications: Video-Based Health Promotion Strategies for COVID-19 Vaccinations
|
N/A | |
| Completed |
NCT05373459 -
Effect of a Third COVID-19 Booster Among Health Care Workers
|
||
| Active, not recruiting |
NCT05571657 -
COVID-19 Booster Dose Reminder/Recall for Adolescents
|
N/A | |
| Completed |
NCT04888793 -
Immune Response to Anti COVID-19 Vaccine in Immunocompromised Patients: a Cohort Study
|
||
| Completed |
NCT04881396 -
Response of Haemodialysis Patients to BNT162b2 mRNA Cov-19 Vaccine
|
||
| Recruiting |
NCT04871165 -
Analysis of Immunogenicity, Safety and Efficacy of COVID-19 Vaccines in Immunosuppressed Individuals
|
||
| Active, not recruiting |
NCT05293665 -
Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine
|
Phase 3 | |
| Active, not recruiting |
NCT05405283 -
Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults
|
Phase 3 | |
| Recruiting |
NCT05508477 -
UNAIR Inactivated COVID-19 Vaccine Phase III (Immunobridging Study)
|
Phase 3 | |
| Recruiting |
NCT05471635 -
Variables Influencing Anti-COVID-19 Vaccinations Around the World: an Analysis Conducted on Aggregated Data Sourced From Institutional Databases to Understand Whether and How Different Variables Could Affect the Vaccine Coverage (WORLDCOV: Worldwide Determinants of COVID-19 Vaccination)
|
||
| Recruiting |
NCT06282692 -
INAVAC Vaccine Phase III (Immunobridging Study) in Healthy Population Aged 12 to 17 Years Old
|
Phase 3 | |
| Completed |
NCT05406908 -
Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases
|
Phase 4 | |
| Recruiting |
NCT05831826 -
Effectiveness and Safety of the Inactivated COVID-19 Vaccine in Thousands of Patients With Autoimmune Diseases in China
|
||
| Recruiting |
NCT05096260 -
Getting to Yes, Michigan! (G2YMI)
|
N/A | |
| Completed |
NCT04962906 -
Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes
|
Phase 2 | |
| Active, not recruiting |
NCT05027672 -
Strategies for Combining the First Component of Sputnik V With Other Adenoviral or mRNA-based Vaccines.
|
Phase 2 |